Snowden Capital Advisors’s Amedisys AMED Stock Holding History

Snowden Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	1069
2021 Q4	$0	Buy	+4	New	+$643	﹤0.01%	2034

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Snowden Capital Advisors's AMED Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Amedisys (AMED) in Q1 2022, closing a stake of 4 shares.

Snowden Capital Advisors first reported a position in AMED in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

Snowden Capital Advisors reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 4 Amedisys shares in Q1 2022.
Snowden Capital Advisors first reported a position in Amedisys in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Amedisys position peaked at $0 in Q4 2021.
328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.